Literature DB >> 15009469

Shiga toxin binds to activated platelets.

S A Ghosh1, R K Polanowska-Grabowska, J Fujii, T Obrig, A R L Gear.   

Abstract

Hemolytic uremic syndrome (HUS) is associated with acute renal failure in children and can be caused by Shiga toxin (Stx)-producing Escherichia coli. Thrombocytopenia and formation of renal thrombi are characteristic of HUS, suggesting that platelet activation is involved in its pathogenesis. However, whether Shiga toxin directly activates platelets is controversial. The present study evaluates if potential platelet sensitization during isolation by different procedures influences platelet interaction with Shiga toxin. Platelets isolated from sodium citrate anticoagulated blood were exposed during washing to EDTA and higher g forces than platelets prepared from acid-citrate-dextrose (ACD) plasma. Platelet binding of Stx was significantly higher in EDTA-washed preparations relative to ACD-derived platelets. Binding of Stx was also increased with ACD-derived platelets when activated with thrombin (1 U mL-1) and exposure of the Gb3 Stx receptor was detected only on platelets subjected to EDTA, higher g forces or thrombin. EDTA-exposed platelets lost their normal discoid shape and were larger. P-selectin (CD62P) exposure was significantly increased in EDTA-washed preparations relative to ACD-derived platelets, suggesting platelet activation. Taken together, these results suggest that direct binding of Stx occurs only on 'activated' platelets rather than on resting platelets. The ability of Stx to interact with previously activated platelets may be an important element in understanding the pathogenesis of HUS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009469     DOI: 10.1111/j.1538-7933.2004.00638.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  Platelet-bacterial interactions.

Authors:  Steven W Kerrigan; Dermot Cox
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

2.  Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Authors:  Fadila Guessous; Marek Marcinkiewicz; Renata Polanowska-Grabowska; Sudawadee Kongkhum; Daniel Heatherly; Tom Obrig; Adrian R L Gear
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.

Authors:  Carla Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2010-04-28       Impact factor: 3.714

Review 5.  Role of Shiga/Vero toxins in pathogenesis.

Authors:  Fumiko Obata; Tom Obrig
Journal:  Microbiol Spectr       Date:  2014-06

6.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

7.  The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.

Authors:  S A Gomez; M J Abrey-Recalde; C A Panek; N F Ferrarotti; M G Repetto; M P Mejías; G C Fernández; S Vanzulli; M A Isturiz; M S Palermo
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 8.  Pathogenesis and prognosis of thrombotic microangiopathy.

Authors:  Masaomi Nangaku; Hiroshi Nishi; Toshiro Fujita
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

9.  Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Majlis Svensson; Matthias Mörgelin; Catharina Svanborg; Phillip I Tarr; Jody C Mooney; Sandra L Watkins; Roger Johnson; Diana Karpman
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

Review 10.  Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.

Authors:  Lindsay S Keir; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2013-07-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.